Emerging role of bisphosphonates in the clinic—Antitumor activity and prevention of metastasis to bone
Author:
- 1 January 2008
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 34, S25-S30
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer PatientsClinical Cancer Research, 2007
- Meta-analysis of clodronate and breast cancer survivalBritish Journal of Cancer, 2007
- Bone Sialoprotein Is Predictive of Bone Metastases in Resectable Non–Small-Cell Lung Cancer: A Retrospective Case-Control StudyJournal of Clinical Oncology, 2006
- Genes Associated With Breast Cancer Metastatic to BoneJournal of Clinical Oncology, 2006
- The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugsProceedings of the National Academy of Sciences, 2006
- Zoledronic Acid-Related Angiogenesis Modifications and Survival in Advanced Breast Cancer PatientsJournal of Interferon & Cytokine Research, 2005
- Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patientsActa Oncologica, 2004
- Bisphosphonates: Clinical ExperienceThe Oncologist, 2004
- Early Detection of Bone Metastases in a Murine Model Using Fluorescent Human Breast Cancer Cells: Application to the Use of the Bisphosphonate Zoledronic Acid in the Treatment of Osteolytic LesionsJournal of Bone and Mineral Research, 2001
- Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?European Journal of Cancer, 1996